Lung cancer is the leading cause of cancer-related deaths in the United States. Filling a gap in the literature, this resource translates recent laboratory findings into practical applications for the prevention and control of lung cancer. Featuring chapters by seasoned researchers in the field, this reference reviews current advances in imaging, drug development, molecular therapeutics, genetics, immunotherapy, and chemotherapy, to stand at the forefront of technologies for patient diagnosis and treatment.
Table of Contents
Molecular Biology of Lung Cancer as the Basis for Targeted Therapy. Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers. Antiangiogenic Therapy for Lung Cancer: Small-Molecule Inhibitors. Antiangiogenic Therapy for Lung Cancer: Antibodies and Other Novel Agents. Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer. Epidermal Growth Factor Receptor Targeted Therapy-Markers of Sensitivity and Response. Other Novel Targeted Therapies in Lung Cancer. Lung Cancer Vaccines. Advances in Chemoradiation Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer. Advances in the Treatment of Brain Metastases. Recent Advances in Imaging for Lung Cancer
KISHAN J. PANDYA is Professor of Medicine and Oncology, Director of the Clinical Trials Office, and Codirector of the Thoracic Oncology Program, James P. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, New York. A member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society for Preventive Oncology, among other organizations, Dr. Pandya has served as a visiting professor at many universities and presented at major national professional meetings. Dr. Pandya received the B.S. and M.B. degrees from Maharaja Sayajirao University, Baroda, India. JULIE R. BRAHMER is Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. The author of numer-ous book chapters, lectures, and professional publications, Dr. Brahmer serves on the editorial board of the Journal of Clinical Oncology. Dr. Brahmer is a member of the American Association for Cancer Research and the American Society of Clinical Oncology, among other organizations, and received the M.D. degree from the University of Nebraska Medical Center, Omaha. MANUEL HIDALGO is Associate Professor of Oncology and Codirector of the Drug Development Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer patients with solid tumors. He received the M.D. degree from the University Navarra Medical School, Pamplona, Spain, and the Ph.D. degree from the University of Autonoma, Madrid, Spain.